Singapore Clinical Trial: A Multicenter, Multi-Part, Phase 1/2 Study of EIK1005 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumors, including Participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) Tumors

Singapore, Nov. 5 -- The Health Sciences Authority received information related to the study titled 'A Multicenter, Multi-Part, Phase 1/2 Study of EIK1005 as Monotherapy and in Combination with Pembro... Read More

Singapore Clinical Trial: A Phase 3, Randomized, Double-Blind, Placebo-controlled, Multicenter, Parallel-group Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder in Participants with Pulmonary Arterial Hypertension (PALM-PAH)

Singapore, Nov. 5 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Randomized, Double-Blind, Placebo-controlled, Multicenter, Parallel-group Study to Evalu... Read More

Clinical Trial: Platelet Transfusion Thresholds in Non-Bleeding Patients

U.S., Nov. 5 -- ClinicalTrials.gov registry received information related to the study (NCT07915284) titled 'Platelet Transfusion Thresholds in Non-Bleeding Patients' on Oct. 18. Brief Summary: This i... Read More

Singapore Clinical Trial: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study to Investigate the Safety and Efficacy of Efimosfermin Alfa in Participants With Biopsy-Confirmed F2- or F3-Stage Metabolic Dysfunction-Associated Steatohepatitis (MASH) (ZENITH-1)

Singapore, Nov. 5 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study to Investigate the Safety and ... Read More

Singapore Clinical Trial: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study to Investigate the Safety and Tolerability of Efimosfermin Alfa in Participants With Known or Suspected F2- or F3-Stage Metabolic Dysfunction-Associated Steatohepatitis (MASH) (ZENITH-2)

Singapore, Nov. 5 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study to Investigate the Safety and ... Read More

Singapore Clinical Trial: A Phase 1, Randomized, Placebo-Controlled, Investigator and Participant Blinded, Single Ascending Dose and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LY4302814 in Healthy Participants

Singapore, Nov. 5 -- The Health Sciences Authority received information related to the study titled 'A Phase 1, Randomized, Placebo-Controlled, Investigator and Participant Blinded, Single Ascending D... Read More

Singapore Clinical Trial: A Global Multicenter, Open Label, Randomized Phase 3 Registrational Study of Olverembatinib Combined with Chemotherapy Versus Investigator’s Choice of TKI Combined with Chemotherapy in Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

Singapore, Nov. 5 -- The Health Sciences Authority received information related to the study titled 'A Global Multicenter, Open Label, Randomized Phase 3 Registrational Study of Olverembatinib Combine... Read More

Clinical Trial: Effect of the 4-7-8 Breathing Technique Before Central Venous Catheter Insertion

U.S., Nov. 5 -- ClinicalTrials.gov registry received information related to the study (NCT07917585) titled 'Effect of the 4-7-8 Breathing Technique Before Central Venous Catheter Insertion' on Oct. 26... Read More

Singapore Clinical Trial: 'Establishing the role of mitomycin C and systemic non-steroidal anti-inflammatory drugs in the post-operative survival of glaucoma drainage devices'

Singapore, Nov. 5 -- The Health Sciences Authority received information related to the study titled ''Establishing the role of mitomycin C and systemic non-steroidal anti-inflammatory drugs in the pos... Read More

Singapore Clinical Trial: IZABRIGHT-Lung01: A Randomized, Open-label, Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-based Chemotherapy in Patients with EGFR-mutated Non-small Cell Lung Cancer and Disease Progression on EGFR Tyrosine Kinase Inhibitor Therapy.

Singapore, Nov. 5 -- The Health Sciences Authority received information related to the study titled 'IZABRIGHT-Lung01: A Randomized, Open-label, Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507)... Read More

• ««
• «
• 4057
• 4058
• 4059
• 4060
• 4061
• 4062
• 4063
• 4064
• 4065
• 4066
• »
• »»